Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer
Introduction Delayed onset of immune‐related adverse events following immune‐checkpoint inhibitor discontinuation is underrecognized because of little available evidence. Case presentation A 50‐year‐old man with metastatic renal cell carcinoma (Case 1) and 58‐year‐old woman with renal cell carcinoma...
Main Authors: | Yasutomo Nakai, Tomoyuki Otsuka, Takako Inoue, Takatoshi Nawa, Koji Hatano, Yoshiyuki Yamamoto, Akira Nagahara, Masashi Nakayama, Ken‐ichi Kakimoto, Kazuo Nishimura |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | IJU Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/iju5.12338 |
Similar Items
-
Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01) -
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
by: Andrew Hantel, et al.
Published: (2018-07-01) -
Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01) -
Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
by: Nobuyuki Nakajima, et al.
Published: (2020-09-01) -
Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report
by: Kuniyasu Takagi, et al.
Published: (2021-10-01)